The share price of Pro Medicus Ltd (ASX: PME) plummeted by 21.94% on Thursday, reaching $132.29 per share. This significant drop has brought the stock down approximately 40% since the beginning of 2026, marking a return to price levels not observed since August 2024. The dramatic decline raises questions about market expectations versus actual performance.
For the six months ending December 31, 2025, Pro Medicus reported impressive financial results, including a 28.4% increase in revenue, amounting to $124.8 million. The underlying profit before tax rose by 29.7% to a record $90.7 million, while the underlying EBIT margin expanded to 72.6%. The company also declared an interim dividend of 32 cents per share, fully franked. Statutory net profit after tax surged to $171.2 million, bolstered by unrealized gains from its investment in 4DMedical.
Despite these robust figures, the sell-off suggests that investor expectations were exceptionally high before the results were released. Pro Medicus had been trading at a premium valuation, which left little room for any disappointment. Management noted that the implementation of its largest contract went live late in October, limiting its contribution to the financial results for the period.
The aftermath of the results has seen the stock facing technical challenges. At its current price of $132, Pro Medicus still holds a market capitalization of approximately $13.8 billion. The company is recognized for its capital-light business model, strong profit margins, and over $1 billion in contracted revenue over the next five years. The North American market remains a significant growth area, particularly with its Visage 7 platform, which is designed to enhance AI-driven workflows.
Nevertheless, the share price decline has compromised recent support levels around $150, which could not withstand the selling pressure. Current trading levels reflect a significant retracement from previous highs, as momentum indicators have weakened considerably. The relative strength index (RSI) is approaching oversold territory, indicating persistent selling activity.
Investors are now faced with a critical decision: should they view this decline as a buying opportunity or a potential value trap? While revenue and margins continue to trend upward, the willingness of investors to pay for these earnings has clearly diminished. Some may interpret the current lower price as a chance to acquire a quality business at a discount, while others might prefer to wait for signs of stabilizing selling pressure.
The attractiveness of this scenario will largely depend on how quickly the recently secured contracts translate into enhanced earnings in the next 12 to 24 months. As the market digests these factors, the future trajectory of Pro Medicus will be closely monitored by analysts and investors alike.
